Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > News > START chosen to test drug compound that suppresses cancer-causing genes

March 13th, 2008

START chosen to test drug compound that suppresses cancer-causing genes

Abstract:
South Texas Accelerated Research Therapeutics (START) has been selected as one of two clinics that will conduct Phase I trials for an anti-cancer compound developed by Calando Pharmaceuticals.

Calando also submitted an investigational new drug application (IND) to the U.S. Food and Drug Administration to initiate the clinical trial for the drug, CALAA-01.

The drug is a targeted nanoparticle designed to activate the body's natural mechanism to "silence" the "inappropriate activity" of specific genes causing cancer. The trial will evaluate whether CALAA-01 is safe and tolerable by humans. Anthony Tolcher, M.D., director of clinical research at START, will be leading the study in San Antonio.

START is a partnership that directs clinical trials of novel anticancer agents and is headquartered at San Antonio's South Texas Medical Center. The group is constructing a new 120,000-square-foot office headquarters building, scheduled to open in July 2008.

Source:
bizjournals.com

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

East China University of Science and Technology Purchases Nanonex Advanced Nanoimprint Tool NX-B200 July 30th, 2014

Watching Schrödinger's cat die (or come to life): Steering quantum evolution & using probes to conduct continuous error correction in quantum computers July 30th, 2014

From Narrow to Broad July 30th, 2014

FLAG-ERA and TNT2014 join efforts: Graphene Networking at its higher level in Barcelona: Encourage the participation in a joint transnational call July 30th, 2014

Nanomedicine

New imaging agent provides better picture of the gut July 30th, 2014

Zenosense, Inc. July 29th, 2014

Optimum inertial design for self-propulsion: A new study investigates the effects of small but finite inertia on the propulsion of micro and nano-scale swimming machines July 29th, 2014

FEI adds Phase Plate Technology and Titan Halo TEM to its Structural Biology Product Portfolio: New solutions provide the high-quality imaging and contrast necessary to analyze the 3D structure of molecules and molecular complexes July 28th, 2014

Announcements

University of Manchester selects Anasys AFM-IR for coatings and corrosion research July 30th, 2014

Nature inspires a greener way to make colorful plastics July 30th, 2014

Analytical solutions from Malvern Instruments support University of Wisconsin-Milwaukee researchers in understanding environmental effects of nanomaterials July 30th, 2014

FEI Unveils New Solutions for Faster Time-to-Analysis in Metals Research July 30th, 2014

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE